URINARY TRACT INFECTION THERAPEUTIC MARKET ANALYSIS

Urinary Tract Infection Therapeutic MarketSize and Trends

Global Urinary Tract Infection Therapeutic Market is estimated to be valued at USD 9.39 Bn in 2024 and is expected to exhibit a CAGR of 3% during the forecast period (2024-2031).

Global Urinary Tract Infection Therapeutic Market Segmentation:

Based on Drug, the market is segmented into Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs. Out of which, Penicillin and Combinations Segment is expected to dominate the urinary tract infection market during the forecast period and this is attributed to the increase in prevalence of urinary tract infections (UTIs). Most penicillins are widely being used directly and in combinations for treating urinary tract infections (UTIs).

Quinolones Segment is also expected to witness significant growth in the near future and this is owing to the increase in demand for novel UTI therapeutic. Quinolones represent a natural alternative to trimethoprim-sulfamethoxazole for treating urinary tract infections (UTIs) when resistance becomes a potential problem.

Global Urinary Tract Infection Therapeutic Market Trends:

The prevalence of UTIs (complicated UTIs) is expected to increase during the forecast period due to the increase in recurrence rate for UTIs, increasing bacterial resistance in UTI cases, and excessive use of antibiotics. This in turn is expected to increase demand for new urinary tract infection therapeutics (drugs) across the world, and this trend is expected to continue over the forecast period, driving the growth of the market.

Moreover, increase in consumer awareness about the association of diabetes and obesity with bladder dysfunction, increase in focus on the development of novel therapeutics, and the rapid deployment of innovative technologies for UTI treatment are among the key trends driving the overall growth of the urinary tract infection therapeutic market.